FDA GRANTS FAST-TRACK DESIGNATION FOR ZACTIMA IN THYROID CANCER

AstraZeneca has announced that the FDA has granted fast-track designation for the investigation of Zactima in treating medullary thyroid carcinoma. For advanced thyroid cancer, there is currently no curative modality or approved chemotherapy. Zactima also received orphan-drug designation last year for the treatment of patients with follicular, medullary, anaplastic, and locally advanced and metastatic papillary thyroid cancer.